FDA Approves FOUNDAYO — Eli Lilly and Company

# FDA Approves Eli Lilly's FOUNDAYO for Oral Administration Eli Lilly and Company received FDA approval for FOUNDAYO (orforglipron calcium), an oral medication that expands the company's therapeutic portfolio and positions it to capture additional market share in the oral pharmaceutical segment. The approval of NDA220934 could strengthen Eli Lilly's competitive standing and drive incremental revenue growth as the company capitalizes on demand for convenient oral treatment options.